Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

OBIO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Orchestra BioMed Holdings, Inc.NASDAQ: OBIO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $90K rose 8.4% year over year, ahead of the +5.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 9.8% from the prior quarter. Over 3 fiscal years it compounded at +13.8% a year.

Context

  • Depreciation & amortization amounted to 1.0% of revenue in FY2025, down 10.7 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +8.4% holds above the trailing-twelve-month pace of +5.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$90K+9.8% QoQ
Last fiscal yearDec 2025
$327K+6.2% YoY
LTMMar 2026
$334K+5.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.4%——
1 year+6.2%——
3-year CAGR+13.8%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
327K USD
Year-over-year change
+6.2%
4-year CAGR
+15.9%

Depreciation & Amortization vs competitors

How OBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.4% is the 5th highest of 11, against a peer median of -11.2%.
  • Depreciation & amortization amounts to 1.0% of revenue for OBIO, versus a peer median of 29.9%.
OBIO Competitors
Depreciation & Amortization for OBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNYATenaya Therapeutics, Inc.LTM Mar 2026$7.54M USD-16.0%-1.1%3350.2%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$4.93M USD+55.9%+19.6%7.1%
PYXSPyxis Oncology, Inc.LTM Mar 2026$4.42M USD+82.7%+85.3%31.9%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$3.13M USD-28.6%+0.0%27.9%
IVAInventiva S.A.FY2025€2.8M EUR-46.2%+47.6%62.4%
IVVDInvivyd, Inc.LTM Mar 2026$1.88M USD-43.4%+65.8%3.4%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$1.67M USD-6.4%+8.9%10.0%
TARAProtara Therapeutics, Inc.LTM Mar 2026$369K USD+11.1%+13.4%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$334K USD+5.4%+13.8%1.0%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$262.3K USD+45.1%+30.9%—
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$226K USD-16.3%+27.5%383.1%
Peer median (excluding OBIO) —-11.2%+23.6%29.9%

Competitors are the stored peer set for OBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Intrinsic Alpha fair value

Locked

Current Price

$7.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.